The pyrimidine analog 5-fuorouracil (5-FU ) is a cytostatic drug that is widely used for the treatment of many solid carcinomas including breast cancer. More than 80 - 85% of administered 5-FU is quickly metabolized in the liver through a series of metabolic steps involving an enzyme dihydropirimidine dehydrogenase (DPD).